This article is part of the supplement: Severe sepsis and drotrecogin alfa (activated)

Review

Practical aspects of treatment with drotrecogin alfa (activated)

Luigi Camporota and Duncan Wyncoll

Adult Intensive Care Unit, Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK

author email corresponding author email

Critical Care 2007, 11(Suppl 5):S7doi:10.1186/cc6158

Published:	19 December 2007

Abstract

In November 2001, drotrecogin alfa (activated) was approved by the US Food and Drug Administration; in August 2002 it was approved by the European Medicines Agency. Since the approval of drotrecogin alfa (activated), however, critical care physicians have been faced with several challenges, namely its costs, selection of patients who are more likely to benefit from it, and the decision regarding when to start drotrecogin alfa (activated) treatment. There are also operational issues such as how to manage the infusion to deliver an effective treatment while minimizing the risk for bleeding, particularly in patients with deranged clotting, at around the time of surgery or during renal replacement therapy. While addressing these issues, this review remains practical but evidence based as much as possible.